Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that specializes in the development, manufacturing, and marketing of a diverse range of pharmaceutical products. Their portfolio includes injectable, intranasal, and inhalation products, as well as complex medications such as biologics derived from living cells and proteins. The company is also focused on creating innovative drug delivery systems tailored for various routes of administration, which enhances the efficacy and convenience of their medications. Notable products include BAQSIMI®, the first and only dry nasal spray for treating severe hypoglycemia, and a range of inhalation aerosols like Primatene® MIST, which delivers epinephrine.

In addition to their established products, Amphastar is committed to advancing their pipeline with proprietary technologies and platforms. Their offerings encompass a variety of injectable medications, including glucagon emergency kits and naloxone for opioid overdose treatment. The company emphasizes quality and innovation in their product development, ensuring that they meet the needs of patients and healthcare providers. With a focus on both generic and proprietary formulations, Amphastar aims to provide effective solutions for critical health conditions while expanding their impact in the biopharmaceutical industry.

United States

Amphastar Pharmaceuticals is a recognized pharmaceutical company that uses state-of-the-art, cGMP-compliant facilities to develop, manufacture, and market biopharmaceutical injectable, intranasal, and inhalation products.

 

In addition to the Corporate Headquarters, Amphastar has five manufacturing facilities in the United States, China, and Europe, along with a state-of-the-art New Drug Research Center.

 

As a commitment to high quality, all Amphastar finished products are manufactured in the United States.

Amphastar Pharmaceuticals

Company Details